CDE Prioritizes Review for Sanofi’s Nexviazyme and WinHealth’s Ravicti
The Center for Drug Evaluation (CDE) website indicates that two drugs have been selected for...
Henlius Biotech’s HanBeiTai sBLA Accepted for HCC Treatment Review
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that a supplementary Biologic License Application (sBLA) for...
Alphamab Oncology Doses First Patient in KN046-209 Study for NSCLC
China-based Alphamab Oncology (HKG: 9966) announced the first patient dosing in the multi-center, open-label Phase...
Roche’s Rozlytrek Wins NMPA Approval for ROS1+ NSCLC Treatment
Swiss pharmaceutical giant Roche’s China unit announced that it has received market approval from the...
EQRx Accelerates US Development of Two Chinese-Licensed Cancer Drugs
US-based pharma EQRx Inc. (Nasdaq: EQRX) has revealed its latest plans to accelerate the US...
Novartis Aims for China to Be Second – Largest Market by 2024
Dan Brindle, head of Novartis AG’s (NYSE: NVS) China operations, recently spoke with Xinhua news...
ESR Group Enters Life Sciences with Zhangjiang NEO Acquisition
Hong Kong-based real estate asset manager ESR Group Ltd (HKG: 1821) has made its first...
ClouDr Partners with Ipsen to Expand Diphereline’s Reach in China
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), known as “ClouDr,” has partnered with...
E-Health Now Raises Funds for Oncology and Cardiovascular Digital Health Products
E-Health Now, a Beijing-based commercial insurance-focused health management service solutions provider, has raised an undisclosed...
KingYee and XINSEC IOT Form Strategic Partnership for Smart Ward Solutions
Shanghai-based KingYee, a leading domestic intelligent medical technology and service provider, has entered into a...
Chongqing Pharscin’s Gabexate Mesylate Passes GQCE as First Generic in China
China-based Chongqing Pharscin Pharmaceutical Co., Ltd (SHE: 002907) announced that its gabexate mesylate has passed...
Bennu Biotherapeutics Raises Over RMB100m in Angel+ Round for Global Pipeline Development
Shanghai-based cell therapy specialist Bennu Biotherapeutics has raised over RMB100 million (USD14.8 million) in an...
Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...
Zelgen Biopharmaceuticals’ Donafenib Receives NMPA Approval for Thyroid Cancer
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that the supplementary New Drug Application...
Siemens Healthineers Q3 2022 Results Show Decline Amid COVID-19 Impact
Siemens Healthineers AG (ETR: SHL) released its financial results for the fiscal year Q3 2022...
Chinese Researchers Map Cancer Genomic Alterations in 10,000 Patients
A team of Chinese researchers led by Wang Minghui at Sun Yat-sen University has conducted...
Longwood Valley Medtech Partners with J&J MedTech on Digital Surgery Biosystem
Beijing-based Longwood Valley Medtech has entered into an in-depth partnership with US major Johnson &...
Elite Pharma Raises RMB100m in Series B Financing for Drug Delivery Tech
Shanghai-based Elite Pharmaceutical Technology Inc. has reportedly raised nearly RMB100 million (USD14.8 million) in a...
WuXi ATU Licenses TESSA Technology to Janssen Biotech for AAV Production
WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused CTDMO unit of WuXi Apptec,...
Medlander Medical Technology’s IPO Raises RMB 1 billion on Shanghai’s STAR Board
Medlander Medical Technology Inc., a leading Chinese manufacturer of pelvic floor rehabilitation equipment, has completed...